Bright Minds Biosciences is working with Firefly Neuroscience, an AI healthcare company, to provide a full analysis of the electroencephalogram data in Bright Minds' Phase 2 clinical trial evaluating ...
Shares of Bright Minds Biosciences on Friday shot higher after pricing a $35 million private placement. The stock was up 70% at $36.86 in pre-market trading. The company said it has priced the private ...
After two days of declines, shares of Bright Minds Biosciences (NASDAQ:DRUG) bounced back in the premarket on Friday with a ~48% rise after the psychedelic drug developer announced a private ...
Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists ...